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Insulin-loaded PLGA microspheres for glucose-responsive release
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University College London, London, UK; cCentral Laboratory, Environmental Monitoring Center of Kunming, Kunming, P.R. China; dSchool of
Basic Medical Sciences, Kunming Medical University, Kunming, P.R. China
ABSTRACT
Porous poly(lactic-co-glycolic acid) (PLGA) microspheres were prepared, loaded with insulin, and then
coated in poly(vinyl alcohol) (PVA) and a novel boronic acid-containing copolymer [poly(acrylamide
phenyl boronic acid-co-N–vinylcaprolactam); p(AAPBA-co-NVCL)]. Multilayer microspheres were gener-
ated using a layer-by-layer approach depositing alternating coats of PVA and p(AAPBA-co-NVCL) on
the PLGA surface, with the optimal system found to be that with eight alternating layers of each coat-
ing. The resultant material comprised spherical particles with a porous PLGA core and the pores cov-
ered in the coating layers. Insulin could successfully be loaded into the particles, with loading capacity
and encapsulation efficiencies reaching 2.83 ±0.15 and 82.6 ± 5.1% respectively, and was found to be
present in the amorphous form. The insulin-loaded microspheres could regulate drug release in
response to a changing concentration of glucose. In vitro and in vivo toxicology tests demonstrated
that they are safe and have high biocompatibility. Using the multilayer microspheres to treat diabetic
mice, we found they can effectively control blood sugar levels over at least 18 days, retaining their glu-
cose-sensitive properties during this time. Therefore, the novel multilayer microspheres developed in
this work have significant potential as smart drug-delivery systems for the treatment of diabetes.
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Introduction
Diabetes is one of the most serious diseases affecting human
health (American Diabetes Association, 2014; Hanson &
Gluckman, 2014; Zimmet et al., 2014). The most effective
strategy to treat this condition is using daily subcutaneous
insulin injections to reduce blood glucose, but in the clinic
such injections can lead to two significant problems (Henry
et al., 1993; Pickup & Keen, 2002). The first is that different
patients have different blood glucose levels and/or body
weights, so to effectively regulate their blood sugar different
doses of insulin are required. To solve this problem, systems
which are glucose-sensitive in physiological conditions (based
for instance on concanavalin, glucose oxidase, or phenylbor-
onic acid) have been widely investigated (Soni et al., 2009;
Liu et al., 2015; Dong et al., 2016). The second problem is
that patients may be uncomfortable with injecting them-
selves daily, and to overcome this challenge scientists have
developed a range of long term sustained-release platforms
based on polymers such as poly(L-lactide) and poly(lactic-co-
glycolic acid) (PLGA). These materials have achieved promis-
ing results, offering long-lasting sustained release (some
function for up to 30–60 days) (Kozuka et al., 2017; Ying
et al., 2017; Yu et al., 2017).
Concanavalin and glucose oxidase are proteins, so
although they are glucose sensitive they are also expensive
and can be immunogenic (Matsumoto et al., 2013).
Phenylboronic acid (PBA)-containing polymers are lower cost,
non-immunogenic, and have wider versatility and better
in vivo stability (Aoki et al., 1996). A range of glucose-respon-
sive materials based on PBA and its derivatives have been
reported, including bulk gels, nanogels and micelles (Ma &
Shi, 2014; Wu et al., 2017; Zhao et al., 2017). However, even
though PBA-containing polymers have good sensitivity for
glucose, the maximum time period over which they can
release a drug loading is 2–5 days (Aminabhavi et al., 2015;
Dong et al., 2016). After this, a further application is required.
Also, once in the body the degradation time for PBA-contain-
ing polymers is rather long (ca. 20–40 days), which could
cause toxicity if the amount of PBA present builds up follow-
ing repeated applications (Winblade et al., 2002; Soriano-
Ursua et al., 2014).
In recent decades, a range of long term sustained-release
materials have been reported (Hou et al., 2016; Huang et al.,
2016; Maulvi et al., 2016). These are commonly based on
PLGA, which is a generally recognized as safe (GRAS) excipi-
ent certified by the FDA. PLGA has attracted particular atten-
tion for the sustained delivery of protein and peptide drugs
(Wang et al., 2015) and can be processed into a number of
different formulation types. Among the most commonly
explored are drug-loaded PLGA microspheres, whose loading
capacity, encapsulation efficiency, release rates and other
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properties have been investigated in detail (Zhang et al.,
2011; Saini et al., 2015; Rodrıguez et al., 2016; Wang et al.,
2016; Zhang et al., 2016b; Yang et al., 2017). The literature
clearly demonstrates that PLGA microspheres are highly suit-
able for use as sustained-release carriers. However, there are
relatively few drug-loaded PLGA microspheres used in the
clinic, and currently available medicines using this technology
are limited to Vivitrol (for the treatment of opioid depend-
ence), Plenaxis (prostate cancer), Risperdal Consta (bipolar
disorder), Nutropin (growth hormone deficiency), Sandostatin
(severe diarrhea), Profact (advanced carcinoma, endometri-
osis) and Decapeptyl (prostate cancer). There are two main
reasons for this. First, the microspheres may exhibit a burst
of release during the first day or so after administration into
the body, which could cause side effects (Zhang et al.,
2016a). Second, although release can be prolonged, it is hard
to control the exact amount of drug released per day (Shi
et al., 2016), which in the context of diabetes could lead to
blood sugar levels not being controlled at a stable and desir-
able level. It would thus be preferable to combine properties
of glucose sensitivity and long-lasting release in a single
microsphere system.
The layer-by-layer (LbL) assembly approach has attracted
attention for the fabrication of multifunctional systems as a
result of giving precise control over the size, shape, compos-
ition, wall thickness and functions of the materials produced
(Xiao et al., 2014; Zhang et al., 2016a; Richardson et al.,
2015). LbL assembly can be used to prepare multilayer films,
microspheres or nanoparticles (Ariga et al., 2013; Yan et al.,
2013; Borges & Mano 2014). Any substrate surface can be
used and the structure is controlled without the requirement
for any specialist equipment. The usage of LbL technology to
coat PLGA microspheres or nanoparticles has been reported
a number of times (Wang et al., 2010; Go et al., 2015; Chai
et al., 2017). For instance, Go et al. (2015) developed multi-
layered polyelectrolyte films incorporating alpha-melanocyte
stimulating hormone and basic fibroblast growth factor. The
layers were successfully deposited on macroporous PLGA
microspheres and the resultant materials were found to have
potential applications in tissue engineering. In addition, Chai
et al. (2017) deposited multilayers of chitosan and alginate
on doxorubicin-loaded PLGA nanoparticles and were able to
use these to control drug release. However, there is much
less work reported into stimuli-responsive coated micro-
spheres (for instance, those which can respond to glucose,
temperature or pH).
A number of authors have explored LbL systems based on
polyhydroxy polymers and those containing boronic acid
units, forming borate/diol complexes through the LbL
approach (Asoh et al., 2015; Nurpeissova et al., 2015; Aly &
El-Mohdy, 2016). Unfortunately, those systems release a drug
load over a relatively short period of time (12 h to 6 days)
and also commonly exhibit an initial burst release. Here, we
seek to overcome these shortcomings by combining, for the
first time, a glucose-sensitive LbL system with a sustained
release PLGA core. To do this, we exploit a novel polymer
[poly(acrylamide phenyl boronic acid-co-N–vinylcaprolactam);
(p(AAPBA-co-NVCL)] prepared recently in our lab (Wu et al.,
2016b) which has been shown to have excellent glucose
sensitivity at physiological pH. In addition, the production
method is simple and the new polymer has excellent bio-
compatibility both in vitro and in vivo.
In this work, insulin-loaded PLGA microspheres with con-
trollable porous structures were first fabricated by a modified
double emulsion method. The LbL approach was then used
to apply poly(vinyl alcohol) and a boronic acid copolymer
sequentially to the surface of the microspheres. The physico-
chemical properties, drug loading and drug release of the
multilayer microspheres were studied in detail. Their glucose
sensitivity and toxicity were also evaluated, both in vitro and
in vivo. To the best of our knowledge, this is the first
example of glucose-sensitive polymer complexes being com-
bined with PLGA microspheres. We believe our findings
should hasten the development of more effective diabetic
treatment regimens.
Experimental section
Materials
Poly(lactic-co-glycolic acid) (PLGA; D,L-lactide/glycolide 50/50;
Mw 12 kDa) was purchased from the Jinan Daigang
Biomaterial Co., Ltd (Jinan, China). Poly(vinyl alcohol) (PVA-
1788, medical grade) was obtained from Xi’an Tianzheng
Medicinal Materials Co., Ltd (Xian, China). 3-Acrylamido phe-
nylboronic acid (AAPBA) was sourced from the Beijing Pure
Chemical Co., Ltd. (Beijing, China), N-vinylcaprolactam (NVCL)
was purchased from Hubei Jusheng Co., Ltd. (Wuhan, China)
and dimethyl formamide (DMF) and 2,2-azobisisobutyronitrile
(AIBN) from the Sinopharm Chemical Reagent Co. (Shanghai,
China). Insulin was obtained from Sigma-Aldrich
(San Francisco, CA). Dimethyl sulfoxide (DMSO), sodium
hydroxide (NaOH) and phosphate buffered saline (PBS) were
purchased from the China National Medicines Corporation
Ltd. (Beijing, China). All solvents used in this work were of
analytical grade.
Microparticle preparation
Poly(acrylamide phenylboronic acid-co-N-vinylcaprolac-
tam) (p(AAPBA-co-NVCL)) synthesis
p(AAPBA-co-NVCL) was synthesized following a previously
reported method (Wu et al., 2016b).
Preparation of PLGA microspheres
Porous PLGA microsphere preparation has been reported
previously, using the water/oil/water (W1/O/W2) double
emulsion solvent evaporation method (Wu et al., 2016c). A
series of formulations were prepared for optimization, which
are detailed in the Results section. For the optimum formula-
tion, the preparation method is as follows. Firstly, 5mg of
insulin was dissolved in 0.1mL of tris-HCl solution (0.5M tris,
with HCl used to adjust the pH to 7.0) and the resultant solu-
tion was immediately added to 10mL of a solution of PLGA
(1% w/v) and ammonium bicarbonate (1% w/v) in dichloro-
methane. The combined solution was subjected to an ultra-
sound treatment for 5min at 120W (SL-900D instrument,
1514 J.-Z. WU ET AL.
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Nanjing Shunliu Instrument Co., Ltd., Nanjing, China) to yield
a W1/O emulsion. Next, the W1/O emulsion was poured into
200mL of a 2% w/v PVA aqueous solution (W2). The result-
ant solution was left under stirring for 5 hours at room tem-
perature, to remove dichloromethane. The PLGA
microspheres were collected by centrifugation (5810 R instru-
ment, Eppendorf, Hamburg, Germany) for 10min at
8000 rpm. After recovery, the microspheres were washed
using distilled water (2 10mL) three times. Finally, they
were dispersed in a 5% w/v mannitol solution prior to freeze-
drying (10 Pa, 50 C; SJIA-10N instrument, Ningbo Dual Ka
Instrument Co., Ltd., Ningbo, China) for 72 h. Analogous
materials were prepared without insulin.
Layer-by-layer assembly on PLGA microspheres
1mL of a suspension of the insulin-loaded PLGA micro-
spheres (20mg/mL) was added to a 0.2% w/v aqueous PVA
solution (10mL). After 5minutes, the microspheres were sep-
arated through centrifugation and washed three times with
NaOH solution (10mL, pH¼ 10.0). The microspheres were
then re-dispersed in water (1mL) and combined with a 0.2%
w/v aqueous p(AAPBA-co-NVCL) solution. After 5minutes the
microspheres were recovered and washed three times with
NaOH solution (10mL, pH¼ 10.0). These two steps were
repeated to give four, eight, or twelve alternating layers.
After the layer deposition process was complete, the micro-
spheres were exposed to an aqueous NaOH solution (50mL,
pH¼ 8.5) for 150 hours to remove any loosely bound molecu-
lar chains. The product was washed with distilled water three
times, then it was transferred to a dialysis tube (MWCO 1000)
and dialyzed against water for 24 h. The water was replaced
every 4 h during this process. Finally, the microspheres were
dispersed in a 5% w/v mannitol solution prior to freeze-dry-
ing (10 Pa, 50 C; SJIA-10N instrument, Ningbo Dual Ka
Instrument Co., Ltd., Ningbo, China). The final microsphere
yield was calculated as follows:
Yield ð%Þ ¼ Mass of lyophilized LBL microspheres ðmgÞ=
½mass of insulin added ðmgÞ
þ total mass of polymer added ðmgÞ  100%
Analogous materials were prepared without insulin.
Characterization
Fourier transform infrared spectroscopy
Infrared (IR) spectra were recorded with a FTIR-1500 spec-
trometer (Shanghai Precision Instrument Co., Shanghai,
China). 2mg of each sample was mixed with 200mg potas-
sium bromide in an agate mortar and then compressed into
a pellet. The measurement range was 4000–400 cm1;
32 scans for each sample were collected at a resolution of
2 cm1.
Zeta potential
The zeta potential was determined for 0.3mg/mL suspen-
sions of the microspheres in deionized water, using a
submicron particle size analyzer (Zeta PALS/90 plus,
Brookhaven Instruments Corporation, Holtsville, NY, USA).
Physical form
The physical form of the drug in the microspheres was first
analyzed using differential scanning calorimetry (DSC;
DSC822 instrument, Mettler Toledo, Columbus, OH, USA).
Accurately weighed samples (ca. 3–5mg) were placed in alu-
minum pans and sealed. The samples were then heated at a
constant rate of 2 C/min from 0 to 100 C under a dry
atmosphere of nitrogen.
X-ray powder diffraction (XRD) patterns of the samples
were recorded on a D/MAX-2500PC instrument (Rigaku,
Tokyo, Japan) supplied with Cu Ka radiation. Diffraction pat-
terns were collected over the 2h range 10–75 with a step
size of 0.01 (2h) and count time of 1 s per step.
Morphology
The PLGA microspheres were re-dispersed in distilled water
and then a drop of the suspension was dropped onto an alu-
minum stub covered with double-sided adhesive tape. The
stub was dried for 1 day in a vacuum desiccator and then
sputter coated with a thin layer of gold under an argon
atmosphere. The coated specimen was examined using scan-
ning electron microscopy (SEM) on a JSM-5600 instrument
(JEOL, Tokyo, Japan).
Circular dichroism
Insulin was extracted from the drug-loaded PLGA micro-
spheres by dissolving ca. 5mg of insulin-loaded microspheres
in a 10mM citrate buffer containing 150mM NaCl (1mL, pH
3.0). The resultant supernatant was collected through centri-
fugation. A fresh insulin solution was prepared using the
same method, and used as a control. The solutions were
then diluted to 0.1mg/mL using pH 7.4 PBS for measure-
ment. Circular dichorism (CD) spectra were obtained on a
Jasco J-810 spectrometer (Jasco, Tokyo, Japan). Samples were
scanned from 190–260 nm, with 10 spectra recorded for each
material at a resolution of 1.0 nm and scanning speed of
100 nm/min. All CD data are expressed as mean residue
ellipticity.
In vitro drug release and degradation studies
10mg of insulin loaded PLGA microspheres were incubated
in a 1.5mL centrifuge tube containing 1mL of 10mM PBS
(pH 7.4). This was placed under agitation (100 rpm) using a
magnetic flea and held at 37 C. A number of tubes were set
up in parallel and after predetermined time points the
release medium was removed and replaced with an equal
volume of fresh buffer. The insulin content of the collected
aliquots was determined using an insulin ELISA kit (China
Institute of Atomic Energy, Beijing, China). Experiments were
run in triplicate for each batch of microspheres. SEM was per-
formed to inspect the microspheres at various time points in
the release experiment, in order to assess their degradation.
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Toxicology studies
All animal experiments were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH
Publication No. 8523, revised 1985). The animals were housed
in controlled environments at 22 C, with 12: 12 h light: dark
cycles and relative humidity of 50 ± 15%. Water and food
were provided ad libitum. All experiments were approved by
the Animal Ethics Committee of Kunming Medical University
(reference 2014002). Forty Kunming mice (20 male and 20
female) weighing approximately 20 g were randomly divided
into three treatment and a control group (10 mice/group).
The treatment groups were daily given intraperitoneal injec-
tions of 10 , 20 or 40mg/kg/d doses of drug-free PLGA micro-
spheres in 1mL/kg of saline solution, respectively. The
control group was given daily intraperitoneal injections
(1mL/kg) of saline solution. After 60 days, the mice were
sacrificed.
Sacrifice and tissue collection
The mice were anesthetized using an intraperitoneal injection
of an aqueous chloral hydrate solution (3% w/v), at a dose of
1mL/kg. They were then sacrificed, samples of blood were
taken and their abdominal cavities were exposed. Liver, lung,
spleen, heart and kidney samples were collected and stored
temporarily in 10% neutral buffered formalin (NBF) prior to
hematoxylin-eosin staining. NBF (pH 7.2–7.4) was prepared
from 100mL of a 40% v/v solution of formaldehyde in water,
anhydrous disodium hydrogen phosphate (6.5 g), sodium
dihydrogen phosphate (4.0 g) and distilled water (900mL).
Hematoxylin-eosin (H&E) staining
Liver, spleen, lung, heart and kidney tissues were recovered
from the 10% NBF solution. Tissue slices were dehydrated,
embedded in paraffin, cut and stained using hematoxylin
and eosin.
Type 2 diabetes model
A Type 2 diabetes mice model was established as reported
previously (Okoduwa et al., 2017). Kunming mice were given a
high-fat diet for 8weeks and then injected once with strepto-
zocin (45mg/kg). The mice were classified as diabetic if their
fasting blood glucose level was greater than 15.6mmol/L for
seven consecutive days. Fifty diabetic mice were randomly
divided into a negative control group, a high fat group and
three groups treated with insulin (an insulin injection group,
one treated with insulin loaded PLGA microspheres and one
with insulin-loaded LbL microspheres). Each group contained
10 animals. Animals in the PLGA and LbL microspheres groups
were given a subcutaneous injection of microspheres (con-
taining 1.5mg of insulin per kg of body weight) once on day
zero of the experiment. The insulin treatment group was
injected daily with a solution containing 60 mg/kg of insulin in
0.5mL of a 1% w/v aqueous sodium acetate solution (giving a
total dose over 25 days of 1.5mg/kg). The high fat and control
groups were injected with 50mg/kg of blank PLGA micro-
spheres once on day zero of the experiment (providing a
mass of microspheres essentially equal to that injected to the
two microsphere treatment groups).
Glucose and serum insulin were recorded every day in the
period of treatment. Before each measurement, mice were
fasted for 12 hours and a blood sample taken from the tail
vein (no gavage was applied). In addition, on days 1, 6, 11,
16 and 21, additional experiments were performed to quan-
tify the fasting blood glucose concentration and insulin lev-
els. 1mL of 10% (w/v) brown sugar water was used for
gavage, and subsequently blood glucose and insulin were
measured from samples taken from the tail vein at hourly
intervals over a 6 h period.
Statistical processing
All experiments were repeated three times. Data are reported
as mean± the standard error of the mean (SEM). Differences
in parameter mean values were analyzed using one-way ana-
lysis of variance (ANOVA) tests, followed by SNK-q multiple
comparisons using the SPSS19.0 software (IBM, Armonk, NY,
USA). Differences were considered statistically significant
when p< .05.
Results and discussion
Preparation of p(AAPBA-co-NVCL) and porous PLGA
microspheres
The first steps in this study were the synthesis of p(AAPBA-
co-NVCL) and the porous PLGA microspheres. Schematics
showing each of these are given in Figure 1(A,B), respect-
ively. Figure 1(C) shows the 1H-NMR spectra of N-vinylcapro-
lactam (NVCL), acrylamide phenylboronic acid (AAPBA) and
p(AAPBA-co-NVCL). Resonances in the spectrum of NVCL
(DMSO-d6) can be seen at d values of: 7.23 (1H, 3-H), 5.81
(2H, 2-H), 4.46 (2H, 4-H), 3.35 (2H, 1-H), 1.62 (2H, 6-H), 2.40
(2H, 5-H) and 1.14 (2H, 7-H). AAPBA has peaks at d (DMSO-
d6) of: 10.09 (1H, 4-H), 8.10-7.25 (phenyl protons), 6.47 (1H,
2-H), 6.20 (1H, 3-H) and 5.75 (2H, 1-H). The spectrum of
p(AAPBA-co-NVCL) has resonances at d of: 9.55 (1H, 1-H),
8.17-7.32 (Hs on phenyl ring), 7.22 (1H, 2-H), 4.33 (1H, 6-H),
3.19 (2H, 5-H), 2.36 (1H, 4-H) and 1.65 (6H, 3-H). Comparing
with the spectra of the monomers AAPBA and NVCL, it is
obvious that the peaks of the ethylene groups have disap-
peared in the spectrum of p(AAPBA-co-NVCL) and are
replaced with resonances at 1–4 ppm. The latter are consist-
ent with the formation of a saturated structure, indicating
that p(AAPBA-co-NVCL) was successfully synthesized. The 1H
NMR data are consistent with the literature (Wu et al.,
2016b).
PLGA microspheres can be produced as monolithic or por-
ous materials. The drug loading into monolithic systems is
generally lower than the porous analogue, but the former
also give less burst release (Zhang et al., 2011). Here, we
opted to use porous systems to give enhanced drug loading
and coated the microspheres to ameliorate the burst release
1516 J.-Z. WU ET AL.
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problem. An SEM image of exemplar microspheres is given in
Figure 1(D). The microspheres are clearly spherical in shape,
with pores visible on their surfaces. The concentration of
ammonium bicarbonate is key in determining the porosity of
the spheres and to optimize this we undertook experiments
with concentrations between 0.5 and 2.5% w/v (see
Supplementary Information, Figure S1). With 0.5% ammo-
nium bicarbonate, the spheres are largely monolithic, with lit-
tle evidence of porosity. At 1.0%, clear porosity is seen, but
increasing the concentration further led to the spheres
increasingly becoming broken and fragmented. Hence, 1%
ammonium bicarbonate was adopted for onward studies.
LbL assembly of multilayer microspheres
As has been reported previously (Wu et al., 2016b), p(AAPBA-
co-NVCL) nanoparticles have glucose sensitivity (see Figure
S2). When injected into mice, insulin loaded p(AAPBA-co-
NVCL) particles were found to be effective over 48 hours and
then begin to lose potency (Wu et al., 2016b). However, the
degradation of p(AAPBA-co-NVCL) in vitro took longer (about
20 to 40 days at 37.5 C), indicating that if these particles
were used clinically then there would be a significant (and
potentially toxic) build-up of p(AAPBA-co-NVCL) in the body.
In contrast, PLGA microspheres can lead to long-term sus-
tained release but have no glucose sensitivity, and commonly
also exhibit an initial burst of release. They thus cannot
respond to changes in physiological conditions in an
appropriate manner (Anselmo & Mitragotri, 2014; Fang et al.,
2014). We attempted to prepare p(AAPBA-co-NVCL)-PLGA
composites using a range of methods, including simple mix-
ing, physical absorption and electrostatic spinning, but in all
cases the resultant systems had poor glucose sensitivity.
The LbL approach has already been used by some authors
to develop glucose-sensitive insulin release systems. Qi et al.
(2015) took poly(acrylic acid) and PBA, and successfully used
the LbL approach to make a multilayer system based on por-
ous calcium carbonate microparticles. In addition, Talusan
et al. (2017) used poly(dimethyl diallyl ammonium chloride),
glucose oxidase and poly(acrylic acid) to deposit multilayer
shells onto insulin-loaded particles by LbL. However, the
insulin release observed was too rapid for clinical use.
In this study, PVA and p(AAPBA-co-NVCL) were deposited
onto porous PLGA microspheres. PVA was incorporated into
the formulation because it can react with the boronic acid
units in p(AAPBA-co-NVCL) to form borate/diol complexes
(see Figure S3). To ensure that the PVA is firmly attached to
the PLGA particles, after the initial deposition of PVA the
microspheres were washed with water at pH 10.0 to fix the
PVA in place (PVA will react with NaOH to become water-
insoluble (Qi et al., 2014)). Figure 2(A,B) depict the synthetic
procedure undertaken to develop the multilayer spheres.
Figure 2(C) presents optical images taken after the
deposition of different numbers of alternating layers of
PVA/p(AAPBA-co-NVCL). After two alternating layers were
deposited, the suspension of PLGA microspheres showed
Figure 1. Preparation of p(AAPBA-co-NVCL) and porous PLGA microspheres. (A) The synthesis process for p(AAPBA-co-NVCL); (B) A schematic representation of the
preparation of porous PLGA microspheres; (C) 1H-NMR spectra of (a) NVCL, (b) AAPBA and (c) p(AAPBA-b-NVCL); (D) SEM images of exemplar insulin-loaded PLGA
particles ((a) 1500; (b) 10,000)
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turbidity. With four layers, the turbidity decreased, with sedi-
mentation appearing to begin. At eight alternating layers,
the microspheres precipitated and after 12 the microspheres
were both precipitated and aggregated. SEM images are
shown in Figure 2(D). The spherical nature and porosity of
the spheres can clearly be seen after deposition of two and
four alternating layers, while after eight the particles are still
spherical but almost all the pores appear to be covered.
When 12 layers were deposited, the spheres are heavily
aggregated, in agreement with the photographs in Figure
2(C). This suggests that the optimum spheres are obtained
after eight alternating layers have been deposited. A TEM
image of these particles is given in Figure 2(E). The pores of
the PLGA particles are clearly covered, although the surface
of the particle is rather rough in nature.
Characterization of the multilayer microspheres
The zeta potential offers a simple route to verify whether
the LbL approach was successful or not (Deng et al., 2013;
Hu & Mi 2014; Wu et al., 2016a; Zhang et al., 2017). Zeta
potential data for LbL assembly of PVA and p(AAPBA-co-
NVCL) onto insulin loaded porous PLGA particles are given in
Figure 3(A). The zeta potential is always negative, but after
an odd number of layers is deposited (when PVA is the exter-
ior) it is rather less negative than with even numbers of
layers and a p(AAPBA-co-NVCL) exterior.
The presence and physical form of insulin in the particles
was assessed using IR spectroscopy, XRD and DSC. IR spectra
are given in Figure 3(B). Insulin shows three amide bands at
1678 (amide I), 1504 (II) and 1228 cm1 (III), respectively. For
PVA, there are characteristic absorption bands at 3410 (O–H
stretching), 2940 (C–H stretching), 1740 (C¼O stretching),
1440 (–CH2– bending), 1260 (C–H bending), 1100 (C–O bend-
ing), and 850 cm1 (C–C bending), respectively. p(AAPBA-co-
NVCL) displays C¼O bending at 1678 cm1, C–H bending
at 1260 cm1 and O–B–O bending at 975 cm1,
respectively. PLGA has C¼O bends at 1758 cm1, C–O–C
bends (1186 cm1) and –CH bends (1456 and 1386 cm1),
respectively.
The spectra of the microparticles are complex, as expected
given the large number of components in them. However, in
all the systems the characteristic PLGA peaks (C¼O, C–O–C
and CH) occur at the same positions as the raw material.
Figure 2. Preparation and images of the multilayer microspheres; (A, B) Schematics illustrating the synthetic procedure; (C) Digital photographs after (a) two, (b)
four, (c) eight and (d) 12 alternating layers being deposited; (D) SEM images of particles coated with (a) two, (b) four, (c) eight and (d) 12 alternating layers; (E) TEM
images of the PLGA microspheres (a) after synthesis and (b) after coating with eight alternating layers of PVA and p(AAPBA-co-NVCL).
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The coated particles display additional absorption bands con-
sistent with the deposited layers: O–B–O bends at 942 and
952 cm1 indicate the presence of p(AAPBA-co-NVCL). In add-
ition, an amide II band can be seen at 1496 cm1 for the
insulin loaded microspheres, confirming the successful load-
ing of insulin.
DSC data are presented in Figure 3(C). An amorphous
relaxation endotherm for PLGA can be seen at 46 C, and a
similar endotherm was seen for p(AAPBA-co-NVCL) at 40 C.
Insulin displays a degradation peak at 88 C. All these tem-
peratures are in agreement with the literature (Xiong et al.,
2009; Guo et al., 2015). PVA has a very high melting point of
>180 C, which is not visible in the DSC data. The relaxation
endotherm of PLGA in the porous microspheres is 47 C, very
close to that of the raw polymer. When the LbL process was
completed, the resultant multilayer microspheres can be
seen to have relaxation endotherms at 46 C (Figure 3(C)).
The signals from insulin and p(AAPBA-co-NVCL) cannot be
seen in the microsphere DSC data, likely because of their low
loadings. This is consistent with the literature (Guo et al.,
2015).
XRD data on the formulations are given in Figure 3(D).
The pure insulin powder appears to be amorphous, with only
broad haloes present in the pattern. There are no clear reflec-
tions for the microsphere formulations, which suggest that
these are all also amorphous materials. The XRD data thus
agree with the DSC findings, confirming the systems to be
solid amorphous dispersions.
Drug loading, encapsulation efficiency and in vitro
drug release
The drug loading and entrapment efficiency are crucial if the
microspheres are to be useful clinically. The processing
parameters used to make the spheres have a significant influ-
ence on both of these, and the optimum conditions have
been found to vary with the drug used (Nan et al., 2014;
Alcala-Alcala et al., 2015; Abulateefeh & Alkilany, 2016; Rafiei
& Haddadi, 2017). A range of different conditions (inner
water phase/oil phase and oil phase/external water phase
ratios; PVA concentration; ultrasound time and speed) were
used to prepare PLGA microspheres and these were coated
with eight alternating layers of PVA and p(AAPBA-co-NVCL).
This resulted in a series of LbL microspheres, which we exam-
ined for drug loading and encapsulation efficiency. The
results are shown in Table S1, from which it is clear that the
Figure 3. Characterization of the multilayer microspheres. (A) The change in zeta potential during the LbL process; (B) FTIR spectra; (C) DSC traces (exo up);
(D) XRD patterns. Legend: (a) Insulin; (b) p(AAPBA-co-NVCL); (c) PVA; (d) PLGA; (e) porous PLGA microspheres; (f) multilayer microspheres; and, (g) insulin loaded
multilayer microspheres.
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optimal experimental parameters are as follows: ultrasonica-
tion for 5min, a 2% w/v PVA solution, and volume ratios
for W1/O and O/W2 of 1 : 100 and 1 : 20, respectively. This
gives the highest drug loading, entrapment efficiency and
process yield (2.83 ± 0.15%, 82.6 ± 5.1% and 59.1 ± 5.7%,
respectively).
The results of in vitro assessments of the microspheres
insulin release properties are given in Figure 4(A). The PLGA
microspheres have many pores on their surfaces through
which insulin can diffuse. Thus, they exhibit a 55% burst of
release at the very beginning of the experiment. This burst is
much reduced for the multilayer microspheres, to around
20%. While the PLGA microspheres can sustain release for 15
days, the multilayer systems extend this to 25 days in PBS.
The latter also show very clear glucose sensitivity
(Figure 4(A)). The insulin release rate is markedly increased
with an increase in the glucose concentration of the release
milieu.
We also explored how the systems respond to a change
in the glucose content in the release medium during the
experiment (Figure 4(A)). When the particles are placed in a
0mg/mL solution of glucose, the insulin release rate is slow.
When they are transferred into a 3mg/mL glucose solution
after 5, 10 or 15 days, the release rate clearly accelerates at
the timepoint when the glucose concentration rises. The
effect of reducing the concentration was also studied (Figure
4(A)). The multilayer particles were initially immersed in
3mg/mL of glucose, where the release rate is rapid. When
they are transferred (after 5 or 10 days) into a glucose-free
buffer, the insulin release rate declines.
Figure 4. In vitro drug release from the insulin loaded microspheres. (A) Insulin release at varied glucose concentrations: (a) constant concentration throughout; (b)
initially no glucose and then transfer to high-glucose conditions; and (c) Initially high-glucose then transfer to a glucose-free medium. Experiments were performed
in triplicate and data are plotted as mean± SEM. (B) CD spectra of insulin released from the multilayer microspheres after 6 hours and fresh insulin. (C) SEM images
of the particles after insulin release for 5, 15 and 25 days from (a, c and e) the porous PLGA microspheres and (b, d and f ) multilayer microspheres.
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In order to be effective, it is vital that the 3D structure of
the insulin is unchanged after incorporation into and release
from the microparticles. This can easily be probed using cir-
cular dichroism (CD) (Liu et al., 2015). Insulin released from
the microspheres was compared to standard insulin (Figure
4(B)). The CD spectrum of the released insulin exhibits typical
a-helical characteristics, with negative elasticity at 208 and
222 nm. The spectra of released and fresh insulin are almost
identical, suggesting that there is no loss of tertiary structure
during the formulation process.
Morphological examinations of the microspheres after
insulin release were undertaken using SEM and images are
presented in Figure 4(C). After five days (Figure 4(C)) the
uncoated PLGA spheres are still intact, but after 15 and 25
days they can be seen to increasingly break down into frag-
ments. This rate of degradation is consistent with previous
reports (Janoria & Mitra, 2007; Nie et al., 2015). Figure 4(C)
also depicts the morphology of the multilayer microspheres.
Throughout the release experiment, the surface of these
remains smooth, with the majority remaining intact after 10
days. The microspheres appear increasingly porous and
aggregated with longer immersion times. This suggests that,
compared to the porous PLGA microspheres, the multilayer
formulation has a longer degradation time in vitro, leading to
extended drug release.
Chronic toxicity
In a previous report (Wu et al., 2016b), we have shown that
p(AAPBA-co-NVCL) is safe in mice in vivo, and PLGA and PVA
are FDA GRAS materials. However, the effects of the combin-
ation of these are not known, and the use of NaOH to fix
PVA could be problematic if there is residual NaOH in the
formulations. First, the cytocompatibility with NIH3T3 cells
was explored; the results after the cells had been exposed to
the various materials for 24 h can be seen in Figure S4. It is
clear that the microspheres have very good biocompatibility,
with viabilities very similar to untreated cells even at concen-
trations of 100 mg/mL.
Although useful, an in vitro analysis is no substitute for in
vivo work, which is also vital to be sure of any potential tox-
icity (Bianco, 2013; Wu et al., 2017; Zhao et al., 2014, 2017).
During in vivo experiments, it was found that none of mice
displayed any discomfort, and all lived for the entire experi-
mental period of 60 days. The findings obtained after sacri-
fice are shown in Figure 5 and Table S2. Figure 5 displays
H&E staining results of the liver, kidney, heart, spleen and
lungs. It can be seen that there is no damage caused to any
of these organs over 60 days, suggesting the multilayer
microspheres to be non-toxic.
Since organ damage can be a slow process (Licata, 2016),
using H&E staining to detect organ pathology may not be
sufficient to uncover toxicity during the experimental time
period. An exploration of biochemical indicators in the blood
can provide additional useful information to pick up the
beginnings of toxic effects (Walker, 1992). The results for a
number of key markers for liver, kidney and heart function
and also inflammation and antioxidant markers are listed in
Table S2. Overall, the coated PLGA microspheres appeared to
have no influence on the blood lipid levels, liver function,
renal function or cardiac function. Inflammatory markers are
somewhat raised and antioxidant capacity was seen to be
reduced at high doses, but not to a level which is thought to
be problematic.
In vivo diabetes model
Quantifying blood glucose and serum insulin can allow both
the hypoglycemic effects of insulin-loaded formulations to be
detected and also characterize insulin release in vivo
(Di et al., 2014; Dhall et al., 2015; Haggag et al., 2016). For
instance, Lei et al. (2016) manufactured a composite hydrogel
system for oral delivery of insulin and used this method to
show that their system could prolong the presence of insulin
in serum. In an another experiment Liu et al. (2017) used a
CaCO3-based composite nanocarrier with the same method-
ology and reached a similar conclusion.
Figure 6 shows the blood sugar and serum insulin profiles
after injection of the insulin loaded multilayer PLGA micro-
spheres into type II diabetes model mice. From Figure 6(A), it
is clear that the blood sugar remained stable for the negative
and positive control groups and the insulin injection group,
throughout the experiment. The negative control and the
insulin injection groups have concentrations in the range of
5– 6mmol/L, while the concentrations in the positive control
group are much higher at 17–23mmol/L. For the PLGA
microspheres group, for the first 7 days after injection the
blood sugar level was stable at 5 to 6mmol/L, but after 7
days the concentration began to rise, reaching ca. 17mmol/L
after 17 days. The multilayer microspheres perform much
better: the blood glucose concentration remains low for 17
days, after which it begins to rise.
The changes in the insulin concentrations in the blood are
also shown in Figure 6(A). Both control groups and the insu-
lin injection group have low concentrations, around
1–3mmol/L. However, after the first day, the insulin concen-
tration is 17.54 ± 1.21 and 15.02 ± 0.46mol/L for the porous
microspheres and multilayer microspheres, respectively. For
both microsphere formulations, there is then a gradual
decrease in concentration until after 17 days this is ca.
3.0mol/L or less. The multilayer microspheres are able to
maintain elevated insulin levels for a longer period of time
than the uncoated porous spheres.
We further examined changes in blood glucose and serum
insulin in more detail, to determine whether glucose sensitiv-
ity was observed. The results are shown in Figure 6(B-F).
These panels show the change in glucose and insulin con-
centrations in the blood over 6 h after the application of a
sugar gavage, with these studies done on days 1, 6, 11, 16
and 21 of the experiment. Up to day 16, the multilayer PLGA
microspheres can effectively lower the blood glucose level
over this 6 h period, with efficacy very similar to the insulin
injection group. At 21 days, their efficacy is reduced in this
regard. However, the porous PLGA microspheres show higher
glucose levels after only 11 days, thus proving the effective-
ness of the multilayer coating. Considering the serum insulin,
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the injection group shows a sharp spike in insulin concentra-
tion after application of the injection, with a peak at around
2 h after injection (which was administered at the same time
as the gavage). For the multilayer microspheres, the amount
of insulin present increases with the rising glucose concentra-
tion, peaking around 1 h after the maximum glucose point
and then declining back to baseline. This occurs throughout
the whole 21 day study, although the effect is weakened
after 16 days. The formulations are thus clearly glucose sensi-
tive in vivo and retain this sensitivity for at least 16 days. In
contrast, the uncoated porous microspheres show no such
sensitivity, with the insulin levels in the blood being essen-
tially constant over the 6 h period of measurement on each
day.
These results are significantly better than the previous
reports in the literature based on PBA systems (Hamishehkar
et al., 2009; Luo et al., 2012). The studies undertaken to date
have not been able to provide the crucial combination of
glucose sensitivity and long-term insulin release. For instance,
Shi et al. (2016) fabricated insulin-loaded polyelectrolyte cap-
sules via the LbL approach; while these had good glucose
sensitivity, insulin release was only sustained over ca.
12–36 h. In other work, Sood et al. (2015) developed a glu-
cose sensitive hydrogel system which modulates the release
of an anti-diabetic drug in response to the blood glucose
level in the body, but the release could only be maintained
for 6–18 h. Luo et al. (2012), fabricated a glucose-sensitive
LbL film using a star polymer, glucose oxidase and catalase
and found a single dose administration could provide effect-
ive glycemic control in diabetic rats for up to 295 days.
However, glucose oxidase can be immunogenic, where as
our materials are not. Our systems are thus notably better in
performance than other reports in the literature and display
glucose sensitivity and insulin release over a long time
period. Hence, they have great potential for the control of
type II diabetes.
Figure 5. HE staining of the liver, kidney, heart, spleen and lung in mice. Images are at 200magnification.
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Conclusions
PVA and the novel copolymer p(AAPBA-co-NVCL) were used
in this work to coat insulin-loaded PLGA microspheres. This
was achieved through layer by layer deposition, successfully
yielding a new multilayer composite which gives long-term
and glucose-responsive release of insulin. It was determined
that coating with eight alternating layers of PVA and
p(AAPBA-co-NVCL) gave the best results in terms of particle
morphology and pore coating. The microspheres produced
had a reasonable loading capacity, high encapsulation effi-
ciency and contained insulin in the amorphous state. An in
vitro release assay confirmed that the multilayer microspheres
were glucose sensitive and altered their insulin release rates
in response to a change of glucose concentration. Release
could be maintained over 15 to 25 days, and the insulin
freed from the microspheres has the same tertiary structure
as native insulin. Cell and animal chronic toxicology studies
confirmed that even if injected once a day at 40mg/kg, the
multilayer microspheres have low toxicity, although with
some increase in the production of inflammatory factors.
Antioxidant capacity is seen to be slightly reduced at the
highest doses. In a mouse model of type II diabetes, it was
shown that the multilayer microspheres are able to reduce
blood sugar concentrations to normal levels and have good
glucose sensitivity in vivo. They retain these properties for at
least 16 days. Therefore, the multilayer microspheres reported
Figure 6. The in vivo efficacy of the multilayer microspheres in a murine model of type II diabetes. The characteristic of glucose concentration and serum insulin,
showing (a) glucose concentration and (b) serum insulin levels over (A) 21 days and more detailed profiles during the 6 h period after gavage on days (B) 1, (C) 6,
(D) 11, (E) 16 and (F) 21. Symbols for groups are as follows:  negative control;  positive control; ~ multilayer microspheres;  insulin injection; and,  porous
PLGA microspheres.
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here have great potential for clinical use and in the long
term offer a potent new approach to the control of diabetes.
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